Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
The two poster presentations cover separate studies that evaluated briquilimab in Mrgprb2-mediated drug-induced anaphylaxis (DIA) and passive systemic anaphylaxis (PSA).
- The two poster presentations cover separate studies that evaluated briquilimab in Mrgprb2-mediated drug-induced anaphylaxis (DIA) and passive systemic anaphylaxis (PSA).
- Results from both studies demonstrated that a single dose of briquilimab protected against anaphylaxis, as measured by significantly higher core body temperatures in animals treated with briquilimab vs. untreated animals.
- The oral presentation covers a study that evaluated briquilimab in allergic asthma, which demonstrated that a single dose of briquilimab significantly reduced the numbers of lung mast cells and bronchoalveolar lavage-recovered eosinophils.
- Additionally, airway-infiltrated eosinophils and neutrophils, as well as airway hyper-responsiveness, decreased in briquilimab-treated mice, suggesting briquilimab has the potential to prevent allergic asthma via mast cell depletion.